astrocytoma, IDH-mutant, grade 3
astrocytoma, IDH-mutant, grade 3
Explore linked clinical trials. Standard reference: MONDO:09569954 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), astrocytoma, IDH-mutant, grade 3, epithelial neoplasm, follicular lymphoma, glioma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 3 | 2026-10-02 | NCT07215910 | |
| Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), astrocytoma, IDH-mutant, grade 2, astrocytoma, IDH-mutant, grade 3, epithelial neoplasm, follicular lymphoma, glioma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 | 2026-09-22 | NCT03528642 | |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), astrocytoma, IDH-mutant, grade 2, astrocytoma, IDH-mutant, grade 3, astrocytoma, IDH-mutant, grade 4, epithelial neoplasm, follicular lymphoma, glioblastoma, glioma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, neuroepithelial neoplasm, oligodendroglioma, primitive neuroectodermal tumor | Recruiting | Phase 3 | 2026-08-28 | NCT05303519 | |
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, anaplastic oligodendroglioma, astrocytoma (excluding glioblastoma), astrocytoma, IDH-mutant, grade 3, astrocytoma, IDH-mutant, grade 4, diffuse astrocytoma, epithelial neoplasm, follicular lymphoma, glioblastoma, glioma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant glioma, neoplasm, neuroepithelial neoplasm, oligodendroglioma, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2026-06-24 | NCT07468136 |